Global Cutaneous T-cell Lymphoma (CTCL) Treatment Market to be Driven by Rising Prevalence of Lymphoma Cancer and Growing Advances in Cancer Treatment at a CAGR of ~5% over 2022-2030
July 15, 2022 10:47 ET
|
Research Nester
New York, July 15, 2022 (GLOBE NEWSWIRE) -- The different types of cancer that arise in the immune cells, also known as lymphocytes, are commonly termed as lymphoma. It is estimated that in the...
North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Size [2022-2028] | to Reach USD 587.4 Million, at a CAGR 13.6%
February 16, 2022 05:48 ET
|
Fortune Business Insights
Pune, India, Feb. 16, 2022 (GLOBE NEWSWIRE) -- North America cutaneous T-cell lymphoma (CTCL) therapeutics market size is projected to hit an annual valuation of USD 587.4 million by 2028,...
Global T-cell Lymphoma Market to Surpass US$ 2,495.4 Million by 2028, Says Coherent Market Insights (CMI)
December 20, 2021 09:00 ET
|
CMI
SEATTLE, Dec. 20, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global T-cell lymphoma market is estimated to be valued at US$ 1,627.1 million in 2021 and is expected to...
Global Cutaneous T-cell Lymphoma Market is projected to be worth USD 3531.5 Million by 2030 I SPER Market Research
November 30, 2021 12:07 ET
|
SPER Market Research Pvt. Ltd.
New York, Nov. 30, 2021 (GLOBE NEWSWIRE) -- The global cutaneous T-cell Lymphoma market is expected to grow at a CAGR of 8.56% from 2020 to reach USD 3531.5 billion by 2030. The growth is primarily...
Promising Treatment for Cutaneous T-cell Lymphoma Enters Clinical Trials
August 03, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Promising Treatment for Cutaneous T-cell Lymphoma Enters Clinical Trials Around 25+ key companies are developing Cutaneous T-Cell Lymphoma...
Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of cutaneous T-cell lymphoma (CTCL)
April 09, 2018 07:00 ET
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, April 09, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation...
TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update
November 04, 2015 16:01 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Nov. 4, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small...
TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata
November 02, 2015 07:00 ET
|
TetraLogic Pharmaceuticals
MALVERN, Pa., Nov. 2, 2015 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that it has an open U.S. Investigational New Drug application in support of a Phase...